Table 1:

Demographics and characteristics of the sample by diagnosis

	AD	MCI	HC	K-W/χ²	P
Sample size, n	37	45	45
Women, %	59.5	31.1	62.2	10.43	.005
Age, y	74.0 ± 7.9	75.7 ± 7.2	76.8 ± 4.9	1.73	.420
Education, y	14.1 ± 3.3	16.3 ± 2.9	16.2 ± 2.2	12.40	.002
CDR (/3)^#	0.8 ± 0.3 (1.0)	0.5 ± 0.1 (0.5)	0 ± 0.1 (0)	141.50	<.001
MMSE (/30)	22.1 ± 4.4	26.4 ± 2.7	28.9 ± 1.2	67.78	<.001
ADAS-cog (/70)	19.6 ± 8.9	12.3 ± 6.0	5.6 ± 3.2	66.54	<.001
Aβ_1–42, pg/mL	149.4 ± 36.1	169.7 ± 44.7	212.9 ± 57.2	16.27	<.001
τ, pg/mL	121.2 ± 47.3	94.7 ± 62.6	68.3 ± 29.1	16.94	<.001
p-τ, pg/mL	45.9 ± 19.5	31.2 ± 15.1	24.6 ± 13.9	17.35	<.001

Note:—Data are presented as mean ± standard deviation, otherwise as indicated. CSF biomarker data were available from a portion of the ADNI sample at baseline (AD = 21, MCI = 28, HC = 23).
CDR indicates Clinical Dementia Rating Scale; MMSE, Mini-Mental State Examination; ADAS-cog, Alzheimer's Disease Assessment Scale–cognitive subscale; Aβ_1–42, amyloid-β-peptides 1–42; τ, total τ protein; p-τ, phospho-τ proteins; K-W/χ², statistics for the Kruskal-Wallis test.